Role of the Immune Environment in Response to Therapy in Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety w wieku 18 lat lub starsze
- •Z nierozsianym rakiem piersi
- •Przechodzące operację usunięcia guza
✗ Disqualifies
- •Mężczyźni
- •Dzieci
- •Kobiety w ciąży
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 8, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Abramson Cancer Center
Philadelphia, United States
Trial contact
Julia T. Lewandowski
Jennifer Zhang, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.